SCHEMBL1471279

SCHEMBL1471279

CCCCCC(O)c1ccc(Cc2ccccc2S(=O)(=O)NCCCCCCC(=O)O)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
LMNA P02545 1/20 0.48
THRB P10828 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CA12 O43570 2/20 0.48
CA9 Q16790 2/20 0.48
TBXA2R P21731 1/20 0.46
RECQL P46063 1/20 0.45
TBXAS1 P24557 2/20 0.44
FABP4 P15090 4/20 0.43
PKLR P30613 1/20 0.42
S1PR2 O95136 1/20 0.41
S1PR1 P21453 1/20 0.41
S1PR3 Q99500 1/20 0.41
LPAR2 Q9HBW0 1/20 0.41
PTGER2 P43116 1/20 0.41
LTB4R Q15722 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471067 0.81 ALDH1A1 (0.53) ALDH1A1LMNATHRBL3MBTL1CA12
SCHEMBL1471098 0.78 LTB4R (0.50) TBXA2RTBXAS1S1PR2S1PR1S1PR3
SCHEMBL12827664 0.74 S1PR1 (0.67) ALDH1A1LMNAS1PR2S1PR1S1PR3
SCHEMBL11128334 0.73 ALDH1A1 (0.67) ALDH1A1LMNATHRBL3MBTL1CA12
SCHEMBL9453929 0.73 CYSLTR2 (0.61) ALDH1A1S1PR2S1PR1S1PR3PTGER2
SCHEMBL5859870 0.72 ALDH1A1 (0.47) ALDH1A1LMNATHRBL3MBTL1TBXA2R
SCHEMBL28318605 0.72 RECQL (0.70) ALDH1A1LMNAL3MBTL1CA12CA9
SCHEMBL4628658 0.72 LTB4R (0.44) S1PR2S1PR1S1PR3PTGER2LTB4R
SCHEMBL8824301 0.71 FABP4 (0.58) ALDH1A1LMNATHRBL3MBTL1TBXA2R
SCHEMBL14000069 0.71 TBXA2R (0.43) ALDH1A1TBXA2RPTGER2LTB4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142471-A1 SULFONAMIDES ALLERGAN, INC. 2007-06-21 US claimed
US-7915316-B2 Sulfonamides ALLERGAN, INC (US) 2011-03-29 US disclosed
EP-1917238-A2 SULFONAMIDES Allergan, Inc. (US) 2008-05-07 EP disclosed
US-20070142471-A1 SULFONAMIDES ALLERGAN, INC. 2007-06-21 US disclosed
WO-2007024860-A2 SULFONAMIDES ALLERGAN, INC. (US) 2007-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142471-A1 SULFONAMIDES CRYZ, QDPR, GLRX3 ALDH1A1 2130/4885LMNA 3009/4885THRB 2401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.